Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Small Cell Lung Cancer News

Conference Coverage
Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/13/2022

Katie Herman

Katie Herman
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues...
12/13/2022
Journal of Clinical Pathways
News
Durvalumab Added to Etoposide Plus Platinum is Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
12/22/2021

Janelle Bradley

Janelle Bradley
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide...
12/22/2021
Journal of Clinical Pathways
News
Anlotinib Safe, Effective as Third- or Later-line Treatment for Refractory SCLC
12/03/2021

Marta Rybczynski

Marta Rybczynski
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study...
12/03/2021
Journal of Clinical Pathways

Advertisement

News
Evolution of Diagnosis and Treatment of SCLC Over the Last 20 Years
10/22/2021

Marta Rybczynski

Marta Rybczynski
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that...
10/22/2021
Journal of Clinical Pathways
News
Third-Line Nivolumab Cost-Effective Compared to Topotecan for SCLC
09/07/2021
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that...
09/07/2021
Journal of Clinical Pathways
News
Durvalumab Plus Chemotherapy Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
09/01/2021
Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.
Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.
Study findings suggest...
09/01/2021
Journal of Clinical Pathways

Advertisement

News
Cost-Effectiveness of First-Line Chemo-Immunotherapy for Extensive-Stage SCLC
08/05/2021
Study findings suggest atezolizumab plus etoposide and platinum chemotherapy is superior to durvalumab plus etoposide and platinum chemotherapy for treating extensive-stage SCLC, though neither strategy was cost-effective compared to...
Study findings suggest atezolizumab plus etoposide and platinum chemotherapy is superior to durvalumab plus etoposide and platinum chemotherapy for treating extensive-stage SCLC, though neither strategy was cost-effective compared to...
Study findings suggest...
08/05/2021
Journal of Clinical Pathways
News
Nivolumab vs Standard of Care for Third-Line Treatment of SCLC
08/04/2021
Study findings show third-line treatment with nivolumab was more effective than standard of care therapy for patients with SCLC in the United States.
Study findings show third-line treatment with nivolumab was more effective than standard of care therapy for patients with SCLC in the United States.
Study findings show third-line...
08/04/2021
Journal of Clinical Pathways
News
Real-World Treatment Patterns and Outcomes Among Patients With SCLC
07/22/2021
A recent systematic review on real-world treatment patterns and outcomes in patients with SCLC found that studies conducted over the last 20 years have failed to report on the impact of recently approved immune-oncology therapies.
A recent systematic review on real-world treatment patterns and outcomes in patients with SCLC found that studies conducted over the last 20 years have failed to report on the impact of recently approved immune-oncology therapies.
A recent systematic review on...
07/22/2021
Journal of Clinical Pathways

Advertisement

News
First-Line Atezolizumab Plus Chemotherapy Not Cost-Effective for SCLC
06/23/2021
A recent cost-effective analysis of first-line treatments for extensive-stage SCLC suggests that atezolizumab plus chemotherapy is not cost-effective in the United States.
A recent cost-effective analysis of first-line treatments for extensive-stage SCLC suggests that atezolizumab plus chemotherapy is not cost-effective in the United States.
A recent cost-effective analysis...
06/23/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use